Stay updated on Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial page.

Latest updates to the Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial page
- Check4 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed, and there are no changes to pricing, stock, or time-slot availability.SummaryDifference0.1%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has added significant content related to a clinical trial, including a new facility name, location details, and a list of relevant publications, while removing various terms and topics related to cancer and treatment that may have been less relevant.SummaryDifference9%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe page has been updated to reflect new results and timelines for the study involving Pembrolizumab and Bevacizumab for treating brain metastases, including changes in response rates and safety assessments. Notably, the study is now marked as completed, and several dates related to results reporting have been added.SummaryDifference11%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial page.